Bayer Aktienges ADR (BAYRY)

$8.06 -0.03 (-0.37%)
Market Cap 31.16B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 5.98
Forward PE 5.89
Profit Margin -5.48%
Debt to Equity Ratio 1.26
Volume 224,338
Avg Vol 624,680
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 23%
Beta 0.90
Analysts Sell
Price Target $8.40

Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
PremarketAnalysis
PremarketAnalysis Oct. 9 at 7:12 PM
$BAYRY fading after brief reclaim. SignalEngine: Bearish 38/62, Algo Vol 21%, Org Vol 78%, BRX 0%. Algo Intent: spoofing tape to stall price action..synthetic flow detected. Momentum Feed: premarketanalysis.com/#momentum=BAYRY
0 · Reply
11thestate
11thestate Oct. 9 at 6:42 PM
$BAYRY has agreed to a $38M settlement with $BAYRY investors to resolve claims it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. The filing deadline is October 16, 2025. If you bought $BAYRY between May 23, 2016, and July 6, 2020, you can file for payment here: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=10092025_1
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 3:39 PM
$BAYRY takes aim at KRAS — one of cancer’s toughest targets. Bayer and Kumquat just kicked off a Phase I study for KQB548, focused on KRAS G12D-mutated tumors including pancreatic, colorectal, and lung cancers — a major step into precision oncology. Full details on the trial and scope here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-teaser-15384&ADID=SYND_STOCKTWITS_TWEET_2_2765555_TEASER_15384
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 2:39 PM
$BAYRY up 62.5% YTD — impressive performance! 🚀 The phase I study for KQB548, targeting KRAS G12D-mutated tumors, marks a big leap in cancer treatment. Plus, Bayer's pipeline is booming with cell and gene therapies, bolstered by acquisitions. Discover the full story here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-body-15368&ADID=SYND_STOCKTWITS_TWEET_2_2765555_BODY_15368
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 5:15 PM
$BAYRY’s BlueRock just delivered strong 36-month results 🧠 Bemdaneprocel continues to show safety and lasting improvement in motor symptoms for Parkinson’s patients — a major validation for this cell therapy approach. See the full data readout here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-teaser-15234&ADID=SYND_STOCKTWITS_TWEET_2_2764774_TEASER_15234
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 4:15 PM
$BAYRY's positive 36-month data for bemdaneprocel in Parkinson's disease shows it's well-tolerated with no adverse events. 💡 🚀 Year to date, shares have surged over 64%, outpacing a 10% industry decline. Discover BAYRY’s promising pipeline here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-body-15233&ADID=SYND_STOCKTWITS_TWEET_2_2764774_BODY_15233
0 · Reply
SpinningRims
SpinningRims Oct. 8 at 2:32 PM
$BAYRY Why the historical downtrend?
1 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 1:13 PM
Pharma rebound in motion — are $NVS, $JNJ, or $BAYRY your next big win? 💊 Pfizer’s landmark pricing deal with Trump is lighting up the drug sector, with Johnson & Johnson, Bayer, and Novartis now looking like prime portfolio contenders. Discover which of these pharma giants could lead the next leg higher 👉 https://www.zacks.com/stock/news/2764279/3-large-drug-stocks-to-watch-as-industry-recovers-after-pfe-trump-deal?cid=sm-stocktwits-2-2764279-teaser-15073&ADID=SYND_STOCKTWITS_TWEET_2_2764279_TEASER_15073
0 · Reply
HereForFunsies
HereForFunsies Oct. 7 at 10:47 AM
$BAYRY another 3% down today?? The volatility here has been wild.
0 · Reply
jagadakku
jagadakku Oct. 2 at 5:01 AM
$BSX $BAYRY money where my experience is
1 · Reply
Latest News on BAYRY
No data available.
PremarketAnalysis
PremarketAnalysis Oct. 9 at 7:12 PM
$BAYRY fading after brief reclaim. SignalEngine: Bearish 38/62, Algo Vol 21%, Org Vol 78%, BRX 0%. Algo Intent: spoofing tape to stall price action..synthetic flow detected. Momentum Feed: premarketanalysis.com/#momentum=BAYRY
0 · Reply
11thestate
11thestate Oct. 9 at 6:42 PM
$BAYRY has agreed to a $38M settlement with $BAYRY investors to resolve claims it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. The filing deadline is October 16, 2025. If you bought $BAYRY between May 23, 2016, and July 6, 2020, you can file for payment here: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=10092025_1
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 3:39 PM
$BAYRY takes aim at KRAS — one of cancer’s toughest targets. Bayer and Kumquat just kicked off a Phase I study for KQB548, focused on KRAS G12D-mutated tumors including pancreatic, colorectal, and lung cancers — a major step into precision oncology. Full details on the trial and scope here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-teaser-15384&ADID=SYND_STOCKTWITS_TWEET_2_2765555_TEASER_15384
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 2:39 PM
$BAYRY up 62.5% YTD — impressive performance! 🚀 The phase I study for KQB548, targeting KRAS G12D-mutated tumors, marks a big leap in cancer treatment. Plus, Bayer's pipeline is booming with cell and gene therapies, bolstered by acquisitions. Discover the full story here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-body-15368&ADID=SYND_STOCKTWITS_TWEET_2_2765555_BODY_15368
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 5:15 PM
$BAYRY’s BlueRock just delivered strong 36-month results 🧠 Bemdaneprocel continues to show safety and lasting improvement in motor symptoms for Parkinson’s patients — a major validation for this cell therapy approach. See the full data readout here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-teaser-15234&ADID=SYND_STOCKTWITS_TWEET_2_2764774_TEASER_15234
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 4:15 PM
$BAYRY's positive 36-month data for bemdaneprocel in Parkinson's disease shows it's well-tolerated with no adverse events. 💡 🚀 Year to date, shares have surged over 64%, outpacing a 10% industry decline. Discover BAYRY’s promising pipeline here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-body-15233&ADID=SYND_STOCKTWITS_TWEET_2_2764774_BODY_15233
0 · Reply
SpinningRims
SpinningRims Oct. 8 at 2:32 PM
$BAYRY Why the historical downtrend?
1 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 1:13 PM
Pharma rebound in motion — are $NVS, $JNJ, or $BAYRY your next big win? 💊 Pfizer’s landmark pricing deal with Trump is lighting up the drug sector, with Johnson & Johnson, Bayer, and Novartis now looking like prime portfolio contenders. Discover which of these pharma giants could lead the next leg higher 👉 https://www.zacks.com/stock/news/2764279/3-large-drug-stocks-to-watch-as-industry-recovers-after-pfe-trump-deal?cid=sm-stocktwits-2-2764279-teaser-15073&ADID=SYND_STOCKTWITS_TWEET_2_2764279_TEASER_15073
0 · Reply
HereForFunsies
HereForFunsies Oct. 7 at 10:47 AM
$BAYRY another 3% down today?? The volatility here has been wild.
0 · Reply
jagadakku
jagadakku Oct. 2 at 5:01 AM
$BSX $BAYRY money where my experience is
1 · Reply
Smartinvestor79
Smartinvestor79 Oct. 1 at 6:49 PM
$BAYRY next stop 9.6
0 · Reply
kgnfdeagle
kgnfdeagle Oct. 1 at 2:21 PM
$BAYRY Bought 1,000 shares at $8.60; Zacks Confidential pick.
0 · Reply
scottptts
scottptts Oct. 1 at 2:13 PM
$BAYRY https://finance.yahoo.com/news/corteva-announces-plan-separate-two-105500295.html
0 · Reply
11thestate
11thestate Sep. 26 at 6:58 AM
$BAYRY has agreed to settle $38 million with investors to resolve claims that it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. Who’s eligible? Anyone who purchased $BAYRY Depository Securities between May 23, 2016 and July 6, 2020. Do I need to sell my shares to qualify? No — eligibility applies whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.23 — but if only ~25% of eligible investors file, the effective payout could increase to $0.92. Can I still file? Yes — the case has a Preliminary Approved Settlement status and claims are being accepted. When do payouts happen? Typically within 8–12 months after final court approval of the settlement. To file your claim: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09262025_1
0 · Reply
Knot2
Knot2 Sep. 23 at 10:39 AM
$KVUE dead money going to be like the $BAYRY and round up fiasco
2 · Reply
flywithfitz81
flywithfitz81 Sep. 23 at 6:45 AM
$KVUE $BAYRY Bayer to Kenvue
0 · Reply
HereForFunsies
HereForFunsies Sep. 22 at 6:03 PM
$BAYRY you'd think we'd have more movement today. This is a big deal for the pharma side! https://www.bayer.com/media/en-us/bayer-first-company-to-advance-cell-therapy-as-well-as-gene-therapy-against-parkinsons-disease/
0 · Reply
jagadakku
jagadakku Sep. 16 at 3:41 PM
$BAYRY I'm adding every chance I get under 8. Hindsight is 20/20 ... I should've just bought my entire position under 5. This is my long term deep value bracket.
0 · Reply
HereForFunsies
HereForFunsies Sep. 16 at 12:11 PM
$BAYRY frustrating to see this back in the 7s
0 · Reply
Broview
Broview Sep. 13 at 7:41 AM
$BAYRY solid business? Please increase dividend
1 · Reply
scottptts
scottptts Sep. 12 at 10:51 PM
$BAYRY https://www.reuters.com/business/agrichemicals-firm-corteva-explores-splitting-seed-pesticide-units-wsj-reports-2025-09-12/
0 · Reply
HereForFunsies
HereForFunsies Sep. 11 at 5:16 PM
$BAYRY like to see this coming back up towards it's 52 week high. Here's to hoping we can set a new high by end of year.
0 · Reply